The UK and US have established a landmark commercial pact that will keep no levies on British medicine products being sold in the US market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has agreed to raise spending on pharmaceuticals through the public health system. This pledge ensures that tariffs on these vital exports will stay at zero for a period of three years.
This deal follows recent warnings to dramatically increase tariffs on patented pharmaceutical imports, with figures floated up to double the cost.
"This agreement between the United Kingdom reinforces the international landscape for innovative medicines and establishes long-overdue fairness to U.S.–U.K. pharmaceutical trade," a release declared.
Economic Significance
Drugs constitute one of the UK's largest exports to the US, which is clearly the largest market for leading companies like GSK and AstraZeneca.
Export figures reveal that in the one-year period prior to last September, the UK exported medicines totaling £11.1bn to the US. This value accounted for nearly one-fifth of total UK exports in that timeframe.
"This agreement safeguards jobs, boosts investment and facilitates the UK to emerge as a international leader for life sciences," a minister commented.
Key British Pledges
The pact involves several key commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new therapies to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to raise overall public funding on medicines from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount drug companies must pay back to the NHS to prevent overspending will be capped at 15%. Previously, rebates were more than twenty percent.
Recent Tensions
The deal takes place against a protracted row between the pharmaceutical industry and the British authorities over spending levels and NHS adoption.
This friction were heightened by claims that American customers were charged a premium for the same drugs than patients in the UK and Europe.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or abandoned, while major funding commitments have been directed toward projects in the United States.
A senior figure acknowledged that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had declined as a share of its total funding over the last ten years.
